drugset / Trial / NCT07661797
Phase I Clinical Study of LNF2105 in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This study is a Phase I clinical trial evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary antitumor efficacy of LNF2105 in patients with advanced solid tumors.
Timeline
- Start
- 2026-06
- Primary completion
- 2028-06
- Completion
- 2028-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LNF2105 | Unknown | 0.3 mg/kg | — |
| Subject | LNF2105 | Unknown | 0.6 mg/kg | — |
| Subject | LNF2105 | Unknown | 1.2 mg/kg | — |
| Subject | LNF2105 | Unknown | 2 mg/kg | — |
| Subject | LNF2105 | Unknown | 3 mg/kg | — |
| Subject | LNF2105 | Unknown | 4.5 mg/kg | — |
Indications
No indication recorded.